Hazeltine M, Rauch J, Danoff D, Esdaile J M, Tannenbaum H
Department of Medicine, Montreal General Hospital, McGill University, Canada.
J Rheumatol. 1988 Jan;15(1):80-6.
Anticardiolipin antibodies (aCL) were evaluated in 65 consecutive patients with systemic lupus erythematosus using an enzyme linked immunoassay (ELISA) and were detected in 14 (22%). There was no association of aCL with active disease, specific clinical manifestations, high DNA binding or circulating immune complex levels. The presence of aCL was associated with lupus anticoagulant activity (p less than 0.001), positive VDRL (p less than 0.05), and lower mean platelet counts (p less than 0.05) and C3 levels (p less than 0.05). Both aCL and lupus anticoagulant activity were associated with positive Coombs' (p less than 0.01) and low C4 (p less than 0.01 and p less than 0.05, respectively). Analysis of red blood cell (RBC) eluates and absorption studies using fixed RBC suggested that some aCL may act as anti-RBC antibodies, likely directed at membrane phospholipid epitopes. Furthermore, we hypothesize that complement may participate as a cofactor maximizing lupus anticoagulant activity.
采用酶联免疫吸附测定法（ELISA）对65例系统性红斑狼疮患者连续进行抗心磷脂抗体（aCL）评估，其中14例（22%）检测到该抗体。aCL与疾病活动、特定临床表现、高DNA结合或循环免疫复合物水平无关。aCL的存在与狼疮抗凝活性（p<0.001）、VDRL阳性（p<0.05）、较低的平均血小板计数（p<0.05）和C3水平（p<0.05）相关。aCL和狼疮抗凝活性均与抗人球蛋白试验阳性（p<0.01）和低C4水平（分别为p<0.01和p<0.05）相关。对红细胞（RBC）洗脱液的分析以及使用固定RBC的吸收研究表明，一些aCL可能作为抗RBC抗体起作用，可能针对膜磷脂表位。此外，我们推测补体可能作为一种辅助因子参与其中，使狼疮抗凝活性最大化。
